

# Market Announcement

17 October 2022

---

## Radiopharm Theranostics Limited (ASX: RAD) – Suspension from Quotation

### Description

The securities of Radiopharm Theranostics Limited ('RAD') will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAD, pending the release of an announcement regarding the analysis of the Pivalate Phase II Data in Brain Mets Trial.

### Issued by

**Angel He**  
Adviser, Listings Compliance (Sydney)

17 October 2022

Angel He  
Adviser, Listings Compliance  
ASX Compliance Pty Ltd  
20 Bridge Street  
Sydney NSW 2000

Via email: [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

Dear Angel

**Radiopharm Theranostics Limited (ASX: RAD)**

**Request for Voluntary Suspension**

Further to the trading halt requested and granted on Thursday 13 October 2022, and in accordance with ASX Listing Rule 17.2, Radiopharm Theranostics Limited (ASX: RAD) (the **Company**) requests voluntary suspension of its securities effective immediately pending release of an announcement to the market about analysis of the Pivalate Phase II Data in Brain Mets Trial expected to be released on Tuesday 18 October 2022.

The Company is not aware of any reason why this voluntary suspension request should not be granted.

Please contact me if you require any further information.

Yours sincerely,

Phillip Hains  
Company Secretary